João Lavrado

João Lavrado

Auto-generated profile, based on publicly available information

João Lavrado

Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
JLJ. Lavrado
J. Lavrado
RMRui Moreira
Rui Moreira
APAlexandra Paulo
Alexandra Paulo
Traditional medicines have contributed greatly over the centuries to the discovery and development of new therapeutic agents and indoloquinoline alkaloids may represent a new class of drug leads. Cryptolepine (5-methyl-5H-indolo[ 3,2-b]quinoline), neocryptolepine (5-methyl-5H-indolo[2,3-b]quinoline), isocryptolepine (5-methyl-5H-indolo[3,2- c]quinoline, extracted from the African medicinal plant Cryptolepis sanguinolenta, and isoneocryptolepine (5-methyl-5H-indolo[ 2,3-c]quinoline), which has never been found in nature, are isomeric tetracyclic compounds of particular interest due to their broad spectrum of biological activities including antiparasitic, antifungal, antibacterial, cytotoxic, antiinflammatory and antihyperglycaemic. As a result, in the last 30 years hundreds of indoloquinoline analogues were synthesized and their biological activities evaluated. In this paper, we present an overview of the potential of indoloquinolines as scaffolds in drug discovery by reviewing the in vitro and in vivo biological activities of natural and synthetic analogues, as well as the proposed mechanisms of action and structure-activity relationships.

8 April 2015 in Scientific Reports
Verified
Journal Article
Open access
JLJoão Lavrado
João Lavrado
HBHugo Brito
Hugo Brito
PBPedro M. Borralho
Pedro M. Borralho
SOStephan A. Ohnmacht
Stephan A. Ohnmacht
NKNam-Soon Kim
Nam-Soon Kim
APAlexandra Paulo
Alexandra Paulo
KRAS is one of the most frequently mutated oncogenes in human cancer, yet remaining undruggable. To explore a new therapeutic strategy, a library of 5-methyl-indolo[3,2-c]quinoline derivatives (IQc) with a range of alkyldiamine side chains was designed to target DNA and RNA G-quadruplexes (G4) in the promoter and 5′-UTR mRNA of the KRAS gene. Biophysical experiments showed that di-substituted IQc compounds are potent and selective KRAS G4 stabilizers. They preferentially inhibit the proliferation of KRAS mutant cancer cell lines (0.22 < IC50 < 4.80 μM), down-regulate KRAS promoter activity in a luciferase reporter assay and reduce both KRAS mRNA and p21KRAS steady-state levels in mutant KRAS colon cancer cell lines. Additionally, IQcs induce cancer cell death by apoptosis, explained in part by their capacity to repress KRAS expression. Overall, the results suggest that targeting mutant KRAS at the gene level with G4 binding small molecules is a promising anticancer strategy.

13 February 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EPEdgar Pereira
Edgar Pereira
LQLetícia Do Quental
Letícia Do Quental
EPElisa Palma
Elisa Palma
MOMaria-Cristina das Neves Oliveira
Maria-Cristina das Neves Oliveira
Filipa MendesFilipa Mendes
Filipa Mendes
António PauloAntónio Paulo
António Paulo
A new family of 99mTc(I)- tricarbonyl complexes and 125I-heteroaromatic compounds bearing an acridine orange (AO) DNA targeting unit was evaluated for Auger therapy. Characterization of the DNA interaction, performed with the non-radioactive Re and 127I congeners, confirmed that all compounds act as DNA intercalators. Both classes of compounds induce double strand breaks (DSB) in plasmid DNA but the extent of DNA damage is strongly dependent on the linker between the Auger emitter (99mTc or 125I) and the AO moiety. The in vitro evaluation was complemented with molecular docking studies and Monte Carlo simulations of the energy deposited at the nanometric scale, which corroborated the experimental data. Two of the tested compounds, 125I-C5 and 99mTc-C3, place the corresponding radionuclide at similar distances to DNA and produce comparable DSB yields in plasmid and cellular DNA. These results provide the first evidence that 99mTc can induce DNA damage with similar efficiency to that of 125I, when both are positioned at comparable distances to the double helix. Furthermore, the high nuclear retention of 99mTc-C3 in tumoral cells suggests that 99mTc-labelled AO derivatives are more promising for the design of Auger-emitting radiopharmaceuticals than the 125I-labelled congeners.

5 January 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JLJoão Lavrado
João Lavrado
GCGhislain G. Cabal
Ghislain G. Cabal
Miguel PrudêncioMiguel Prudêncio
Miguel Prudêncio
MMMaria M. Mota
Maria M. Mota
JGJiri Gut
Jiri Gut
APAlexandra Paulo
Alexandra Paulo

1 July 2008 in Marine Pollution Bulletin
Verified
Journal Article
Closed access
Carlos Alberto Garcia Do ValeCarlos Alberto Garcia Do Vale
Carlos Alberto Garcia Do Vale
João CanárioJoão Canário
João Canário
MCMiguel Jose Martins Caetano
Miguel Jose Martins Caetano
JLJoão Lavrado
João Lavrado
Pedro Aboim BritoPedro Aboim Brito
Pedro Aboim Brito

1 December 2012 in Phytomedicine
Verified
Journal Article
Closed access
LSL.F. Rocha e Silva
L.F. Rocha e Silva
AMA. Montoia
A. Montoia
RAR.C.N. Amorim
R.C.N. Amorim
MMM.R. Melo
M.R. Melo
MHM.C. Henrique
M.C. Henrique
APAdrian Martin Pohlit
Adrian Martin Pohlit